Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation in early infancy
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Martines, J. | - |
dc.date.accessioned | 2015-01-18T05:46:12Z | - |
dc.date.available | 2015-01-18T05:46:12Z | - |
dc.date.issued | 1998 | - |
dc.identifier.citation | Lancet 1999 Jan 9 ; 353(9147) : 154 | en |
dc.identifier.uri | http://hdl.handle.net/123456789/5636 | - |
dc.description.abstract | Abstract BACKGROUND: The benefits and safety of vitamin A supplementation linked to immunisation in infancy need to be assessed before it can be widely recommended. We assessed the safety and benefits of maternal postpartum and infant vitamin A supplementation administered with each of the three diphtheria-tetanus-pertussis (DPT) and poliomyelitis immunisations and with a fourth dose with measles immunisation. METHODS: From January, 1995, we enrolled 9424 mother-infant pairs from Ghana, India, and Peru in this randomised, double-blind, placebo-controlled trial. 4716 mothers of infants in the vitamin A group received 200000 IU vitamin A, and their infants were given 25000 IU vitamin A with each of the first three doses of DPT/poliomyelitis immunisation at 6, 10, and 14 weeks. In the control group, 4708 mothers and their infants received placebo at the same times. At 9 months, with measles immunisation, infants in the vitamin A group were given a further dose of 25000 IU and those in the control group received 100000 IU vitamin A. Infants were followed up to age 12 months. The primary outcome measures were vitamin A status, signs of acute toxic effects, anthropometric indicators, and severe morbidity. Analysis was by intention to treat. FINDINGS: 3933 (93%) of the eligible 4212 infants on vitamin A and 3938 (93%) of the eligible 4227 controls received all four study doses. At the 6-month follow-up, there was a small decrease in vitamin A deficiency in the vitamin A group compared with controls (serum retinol < or =0.70 micromol/L 101 [29.9%] vs 122 [37.1%; 95% CI of the difference -14.3% to -0.2%]). This effect was no longer apparent at 9 and 12 months. There were no significant between-group differences in mortality throughout the study. The rate ratio to compare all deaths up to age 9 months in the two groups was 0.96 (95% CI 0.73 to 1.27). Fewer than 1% of the infants had bulging fontanelle. The intervention had no effect on anthropometric status, or on overall or severe morbidity. INTERPRETATION: The trial confirmed the safety of the intervention, but shows no sustained benefits in terms of vitamin A status beyond age 6 months or infant morbidity | en |
dc.format.extent | 72938 bytes | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | en | en |
dc.subject | Measles vaccine | en |
dc.subject | Vitamin A | en |
dc.subject | Poliovirus vaccine, inactivated | en |
dc.subject | Double-blind method | en |
dc.subject | Postpartum period | en |
dc.subject | Milk, human | en |
dc.subject | Infant, newborn | en |
dc.subject | Vitamin A Deficiency/prevention & control | en |
dc.title | Randomised trial to assess benefits and safety of vitamin A supplementation linked to immunisation in early infancy | en |
dc.type | Article | en |
Appears in Collections: | A. Original papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1998-Lancet-1257-MartinesJ.pdf | 71.23 kB | Adobe PDF | View/Open Request a copy |
This item is protected by original copyright |